Key result
Cerebral embolic protection devices show no consistent stroke reduction during TAVR.
Why the study?
Stroke remains a persistent complication after TAVR with significant morbidity, and optimal prevention strategies are not well established.
Do cerebral embolic protection devices, pharmacologic strategies, or left atrial appendage closure reduce the risk of stroke in patients undergoing TAVR?
Do cerebral embolic protection devices, pharmacologic strategies, or left atrial appendage closure reduce the risk of stroke in patients undergoing TAVR?
Current evidence shows that cerebral embolic protection does not consistently reduce stroke risk during TAVR, necessitating individualized strategies to balance thromboembolic and bleeding risks.
Transcatheter aortic valve replacement (TAVR) is the standard treatment for severe aortic stenosis, yet stroke remains a persistent complication with significant morbidity. This review summarizes the incidence, timing, mechanisms, and predictors of TAVR-related stroke, highlighting procedural embolization and patient comorbidities. We examine evidence for cerebral embolic protection devices, pharmacologic strategies, and left atrial appendage closure in mitigating risk. Despite advances in technology, randomized trials have not shown consistent stroke reduction with embolic protection. Optimal prevention requires individualized strategies balancing thromboembolic and bleeding risks across acute, subacute, and late post-TAVR periods.
No takes yet. Share an insight, caveat, or question.
Patel et al. (2026) conducted a review in Severe aortic stenosis. Cerebral embolic protection devices and pharmacologic strategies was evaluated. Cerebral embolic protection devices have not shown consistent stroke reduction in randomized trials of patients undergoing transcatheter aortic valve replacement.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: